Floatz logo

MANNITOL

Short Bowel Syndrome

Northwestern UniversitySmall moleculePhase 4 / ApprovedDormant
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Short Bowel Syndrome cohort.

Asset / SponsorPhaseRating
Sucralose
Northwestern University
Phase 4BB
LACTULOSE
Northwestern University
Phase 4BB
Genotropin
Northwestern University
Phase 4BB
Glepaglutide
Zealand Pharma
Phase 3B
Loperamide
Odense University Hospital
Phase 3B

View all 10 →

Same molecule, other indications

MANNITOL is also rated in:

cystic fibrosisDormant
BB
Indicative ·
69 / 100
View asset →
Intracranial HypertensionDormant
BB
Indicative ·
67 / 100
View asset →
traumatic brain injuryDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →